免疫检查点抑制剂相关肺结核的药物警戒研究
本研究利用FDA不良事件报告系统数据库,对免疫检查点抑制剂(ICIs)相关肺结核(PT)病例报告进行比例失调分析。共识别74例ICIs相关PT病例,ICIs与PT报告频率显著相关(ROR=3.16,95%CI:2.51-3.98),抗PD-1/PD-L1与抗CTLA-4药物间信号存在差异。多数适应证为肺癌(64.9%),中位发病年龄70岁,中位发病时间70天,大多数病例停用ICIs(85.2%)。
要点
- ICIs治疗与肺结核报告频率显著相关(ROR=3.16),需警惕结核再激活。
- 抗PD-1/PD-L1与抗CTLA-4药物的结核信号存在差异。
- ICIs相关肺结核中位发病时间70天,多数病例需停用ICIs。
核心结论
- ICIs治疗与肺结核报告频率显著相关,ROR=3.16(95%CI:2.51-3.98)。
研究设计与样本
- 基于FDA不良事件报告系统数据库的药物警戒研究,采用报告比值比(ROR)及95%CI进行比例失调分析。
- 共识别74例ICIs相关肺结核病例。
主要发现
- ICIs与PT报告频率显著相关(ROR=3.16,95%CI:2.51-3.98)。
- 抗PD-1/PD-L1与抗CTLA-4药物间信号存在差异。
- 多数适应证为肺癌(64.9%),中位发病年龄70岁,中位发病时间70天。
- 大多数病例停用ICIs(85.2%)。
临床怎么用
- 使用ICIs治疗时,尤其肺癌患者,应警惕肺结核的发生或再激活。
- ICIs治疗中位70天左右需关注结核相关症状筛查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We examined case reports of immune checkpoint inhibitors (ICIs) associated pulmonary tuberculosis (PT) using data from the Food and Drug Administration Adverse Event Reporting System database. Disproportionality analysis was performed by using the reporting OR (ROR) with relevant 95% CI. A total of 74 cases of PT related to ICIs therapy were identified. ICIs were significantly associated with over-reporting frequencies of PT (ROR=3.16, 95% CI: 2.51 to 3.98), while the signal was differed between anti-programmed death-1/ligand-1 and anti-cytotoxic T lymphocyte antigen-4 agents. Most indications were lung cancer (64.9%), the median onset age was 70 years, the median time to onset of PT was 70 days, ICIs were discontinued in most cases (85.2%).
引用
- Zhu J, He Z, Liang D, et al. Pulmonary tuberculosis associated with immune checkpoint inhibitors: a pharmacovigilance study. Thorax. 2022. PMID: 35277447. doi:10.1136/thoraxjnl-2021-217575
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。